Synergistic Zika Virus Vaccine and Surveillance System

A novel system integrating a recombinant measles virus expressing Zika virus prM and E proteins with AI, IoT, blockchain, and advanced materials to enhance vaccine efficacy, track outbreaks, and enable personalized vaccine development.

The original patent for a recombinant measles virus expressing Zika virus prM and E proteins addressed the need for an effective Zika virus vaccine. However, the patent's limitations include the lack of integration with advanced technologies to enhance vaccine efficacy, track outbreaks, and enable personalized vaccine development. The new inventive concept addresses these limitations by combining the recombinant measles virus with AI, IoT, blockchain, and advanced materials.

The synergistic system comprises a recombinant measles virus expressing Zika virus prM and E proteins, which serves as a vaccine candidate. The system integrates an artificial intelligence module to optimize vaccine efficacy based on genomic analysis of Zika virus strains. Additionally, the system includes a blockchain-based platform integrated with IoT sensors for tracking Zika virus outbreaks and a graphene-based nanoparticle for enhanced vaccine delivery and efficacy. Furthermore, the system incorporates a machine learning algorithm for predicting individual immune responses to different Zika virus strains, enabling personalized vaccine development. The system also features a real-time monitoring method using IoT-enabled sensors and a blockchain-based data storage system.

The new inventive concept is novel and non-obvious due to the synergistic combination of the recombinant measles virus with AI, IoT, blockchain, and advanced materials, which provides a more effective and comprehensive approach to Zika virus vaccine development and surveillance.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT sensor configurations, or blockchain platforms. Additionally, the system could be adapted for use with other viruses or diseases, or integrated with other advanced technologies such as CRISPR gene editing or synthetic biology.

The synergistic Zika virus vaccine and surveillance system has significant commercial potential in the vaccine development and public health surveillance markets. The system's ability to enhance vaccine efficacy, track outbreaks, and enable personalized vaccine development addresses a critical need in the global healthcare industry.